Phospho-STK39 (Ser325) Antibody

What is STK39/SPAK and what biological functions does it serve?

STK39 (serine/threonine kinase 39), also known as SPAK (STE20/SPS1-related proline-alanine-rich protein kinase), is a 59.5 kDa protein that functions as an effector serine/threonine-protein kinase component of the WNK-SPAK/OSR1 kinase cascade. This cascade plays crucial roles in ion transport, hypertonic stress response, and blood pressure regulation. STK39 specifically recognizes and binds proteins containing an RFXV motif and acts downstream of WNK kinases (WNK1, WNK2, WNK3, or WNK4) .

The protein is primarily activated in response to hypotonic stress and subsequently phosphorylates several cation-chloride-coupled cotransporters. When catalytically active, STK39 specifically activates the p38 MAP kinase pathway. Notably, its interaction with p38 decreases under cellular stress conditions, suggesting STK39 serves as an intermediate in cellular stress response pathways .

What is the significance of Ser325 phosphorylation in STK39 function?

Phosphorylation at Ser325 represents an important post-translational modification of STK39 that affects its functional properties. While phosphorylation at Thr-231 by WNK kinases is required for STK39 activation, and autophosphorylation at this site positively regulates its activity, Ser325 phosphorylation provides another regulatory mechanism . This specific phosphorylation site is highly conserved and likely plays a role in fine-tuning STK39's interaction with its substrates, including cation-chloride cotransporters such as NCC and NKCC2, which are critical for renal salt excretion .

The Ser325 phosphorylation state can serve as a biomarker for STK39 activity in various physiological and pathological contexts, particularly in studies focusing on blood pressure regulation and renal sodium handling .

What are the recommended applications for Phospho-STK39 (Ser325) antibody?

Based on vendor validation data, Phospho-STK39 (Ser325) antibody is suitable for the following applications:

The antibody has been particularly validated for detecting endogenous levels of STK39 protein only when phosphorylated at Ser325, making it valuable for examining the phosphorylation status of STK39 in various experimental conditions .

How should Phospho-STK39 (Ser325) antibody be stored and handled to maintain optimal performance?

For optimal performance of Phospho-STK39 (Ser325) antibody, follow these storage and handling guidelines:

• Long-term storage: Store the antibody at -20°C for up to one year from the date of receipt.

• Short-term storage: For frequent use within one month, store at 4°C.

• Avoid repeated freeze-thaw cycles as they can damage antibody structure and reduce activity.

• The antibody is typically provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as preservatives.

• When handling, always wear appropriate personal protective equipment due to the presence of sodium azide in the storage buffer .

Following these guidelines ensures maximum antibody stability and performance for your experimental applications.

What controls should be incorporated when working with Phospho-STK39 (Ser325) antibody?

Implementing appropriate controls is essential for reliable results when using Phospho-STK39 (Ser325) antibody:

• Positive control: Use tissues or cell lines known to express phosphorylated STK39, such as brain tissue (as validated in immunohistochemistry applications) .

• Negative control:

  • Omit primary antibody but include all other steps in your protocol

  • Use samples treated with lambda phosphatase to remove phosphorylation

• Blocking peptide control: Use the synthetic phosphopeptide that corresponds to the immunogen (amino acids 291-340 of human STK39 surrounding the Ser325 phosphorylation site). This blocking peptide can be used to confirm antibody specificity, as demonstrated in validation images where signal disappears when the antibody is pre-incubated with the phospho-peptide .

• Non-phospho control: Compare results with a non-phospho-specific STK39 antibody to distinguish between changes in phosphorylation status versus total protein expression.

These controls help validate experimental findings and ensure that observed signals are specific to phosphorylated Ser325 on STK39 .

What are effective methods for validating Phospho-STK39 (Ser325) antibody specificity?

To validate the specificity of Phospho-STK39 (Ser325) antibody, consider these approaches:

• Phospho-ELISA comparison: Perform ELISA using both phospho-peptide (containing phosphorylated Ser325) and non-phospho-peptide versions of the same sequence. Specific antibodies should show significantly higher reactivity with the phospho-peptide, as demonstrated in validation studies .

• Blocking peptide experiments: Pre-incubate the antibody with the phospho-peptide immunogen before application to samples. Signal abolishment confirms specificity for the phospho-epitope, as shown in IHC validation images where brain tissue staining was blocked by phospho-peptide .

• Phosphatase treatment: Treat one set of samples with lambda phosphatase before antibody application. Loss of signal in treated samples confirms phospho-specificity.

• Genetic models: If available, use STK39 knockout models or cells with CRISPR-edited S325A mutation (preventing phosphorylation) as negative controls.

• Kinase activation/inhibition: Stimulate or inhibit upstream kinases (such as WNK kinases) that affect STK39 phosphorylation and confirm corresponding changes in antibody signal .

These validation approaches ensure that observed signals specifically represent Ser325-phosphorylated STK39 rather than non-specific binding or detection of other phosphorylated proteins.

How does STK39 phosphorylation relate to the WNK kinase signaling pathway?

STK39 (SPAK) is a critical downstream component of the WNK (With No Lysine [K]) kinase signaling pathway. This relationship involves several key aspects:

• Activation mechanism: WNK kinases (WNK1, WNK2, WNK3, or WNK4) phosphorylate STK39 at Thr-231, which is required for its activation. While Ser325 represents a different phosphorylation site, its status may be influenced by WNK activity or other upstream signals .

• Substrate interaction: Activated STK39 subsequently phosphorylates downstream targets, including cation-chloride cotransporters such as NCC (Na⁺-Cl⁻ cotransporter) and NKCC2 (Na⁺-K⁺-2Cl⁻ cotransporter), which are critical for renal salt handling .

• Physiological cascade: The WNK-SPAK pathway forms a kinase cascade that regulates ion transport in multiple tissues, particularly in the distal nephron of the kidney where it influences sodium reabsorption and potassium secretion.

• Disease relevance: Mutations in WNK kinases cause Gordon syndrome (pseudohypoaldosteronism type II), a rare form of hypertension. Similarly, genetic variants in STK39 have been associated with blood pressure regulation through genome-wide association studies .

Monitoring STK39 phosphorylation at sites like Ser325 can provide insights into the activation status of this signaling pathway in various physiological and pathological contexts, making phospho-specific antibodies valuable tools for investigating this cascade .

What is the relationship between STK39 phosphorylation and hypertension?

The relationship between STK39 phosphorylation and hypertension is multifaceted:

• Genetic association: Genome-wide association studies have identified common variants in the STK39 gene associated with blood pressure regulation. In Amish subjects and other Caucasian populations, specific STK39 variants were associated with increases of 3.3/1.3 mmHg in systolic/diastolic blood pressure, respectively .

• Mechanistic pathway: STK39, when phosphorylated and activated, regulates the activity of ion cotransporters in the kidney, specifically NCC and NKCC2. These transporters are directly involved in renal salt reabsorption, a key determinant of blood pressure .

• Molecular integration: STK39 provides a link between the WNK kinase pathway (mutations in which cause monogenic forms of hypertension) and more common forms of blood pressure dysregulation. This suggests a unified physiological pathway where both rare and common BP-regulating alleles operate .

• Functional evidence: Cell-based studies demonstrated that STK39 interacts with WNK kinases and cation-chloride cotransporters. In vivo, STK39 is expressed in the distal nephron where these interactions occur, providing a biological basis for its role in blood pressure regulation .

• Transcriptional regulation: Although associated SNPs don't alter STK39 protein structure, functional studies identified a highly conserved intronic element with allele-specific transcription activity. This suggests that variants may influence blood pressure by altering STK39 expression levels rather than protein function directly .

Studying STK39 phosphorylation, including at Ser325, may provide insights into how this kinase contributes to blood pressure regulation and potentially identify new therapeutic targets for hypertension .

What experimental approaches are recommended for investigating STK39 interactions with cation-chloride cotransporters?

To effectively study STK39 interactions with cation-chloride cotransporters, consider these experimental approaches:

• Co-immunoprecipitation (Co-IP): Use anti-phospho-STK39 (Ser325) antibody to pull down STK39 and blot for cotransporters (NCC, NKCC1, NKCC2) to detect physical interactions. Alternatively, perform reverse Co-IP using antibodies against cotransporters.

• Proximity ligation assay (PLA): This technique can visualize protein-protein interactions in situ with high sensitivity, ideal for examining STK39-cotransporter interactions in fixed kidney tissue sections or cultured cells.

• Phosphorylation assays: Since STK39 phosphorylates these cotransporters, use in vitro kinase assays with recombinant STK39 and cotransporter substrates. Follow with phospho-specific antibodies against known phosphorylation sites on cotransporters to assess kinase activity.

• Cell-based assays with mutagenesis: Create phospho-mimetic (S→D) or phospho-null (S→A) mutations at Ser325 of STK39 and assess effects on:

  • Cotransporter phosphorylation

  • Membrane localization of cotransporters

  • Ion transport activity using radioactive isotopes or fluorescent indicators

• Ex vivo kidney slice models: Apply the phospho-STK39 antibody in kidney slice preparations to visualize localization in the distal nephron where it co-expresses with these cotransporters. Challenge with osmotic stress to observe dynamic changes .

• Animal models: Utilize STK39 knockout or phospho-mutant models to evaluate in vivo effects on cotransporter expression, phosphorylation, and activity in relation to salt handling and blood pressure regulation .

These approaches provide complementary information about the functional relationship between STK39 phosphorylation and cotransporter regulation, which is central to understanding hypertension mechanisms.

What factors might cause inconsistent results when using Phospho-STK39 (Ser325) antibody?

Several factors can contribute to inconsistent results when using Phospho-STK39 (Ser325) antibody:

• Sample preparation issues:

  • Inadequate preservation of phosphorylation: Phosphatase activity during sample collection and processing can dephosphorylate Ser325. Use phosphatase inhibitors immediately during sample collection.

  • Overfixation: Excessive formalin fixation can mask epitopes in IHC applications. Optimize fixation time and consider antigen retrieval methods.

• Technical variables:

  • Antibody dilution: Suboptimal antibody concentration can lead to weak signals or high background. Titrate antibody using recommended dilution ranges (IHC 1:100-1:300, ELISA 1:5000, IF 1:50-200) .

  • Incubation conditions: Variations in temperature, time, and buffer composition can affect antibody binding.

  • Detection methods: Different secondary antibodies or visualization systems vary in sensitivity.

• Biological variables:

  • Basal phosphorylation levels: STK39 Ser325 phosphorylation may be low in unstimulated conditions, requiring appropriate positive controls.

  • Tissue-specific expression: STK39 expression varies across tissues; kidney and brain show notable expression .

  • Stimulation conditions: Osmotic stress or other stimuli may need optimization to induce detectable phosphorylation.

• Antibody handling:

  • Repeated freeze-thaw cycles: This can degrade antibody quality. Aliquot upon receipt.

  • Storage conditions: Improper storage temperatures accelerate antibody deterioration .

• Specificity considerations:

  • Cross-reactivity: The antibody might recognize similar phospho-epitopes on related proteins.

  • Lot-to-lot variation: Different manufacturing lots may show slight variations in performance.

Careful optimization and consistent experimental protocols can mitigate these issues and improve reproducibility.

How should changes in STK39 phosphorylation be interpreted in relation to WNK kinase pathway activation?

Interpreting changes in STK39 phosphorylation in relation to WNK kinase pathway activation requires careful consideration of several aspects:

• Directional relationship: Increased WNK kinase activity typically leads to enhanced STK39 phosphorylation, particularly at Thr-231. While Ser325 phosphorylation may follow a similar pattern, it could also be regulated by additional kinases or feedback mechanisms. Therefore, changes in Ser325 phosphorylation should be interpreted within the broader context of WNK pathway activation .

• Temporal dynamics: WNK activation may precede changes in STK39 phosphorylation. Time-course experiments can help establish the sequence of phosphorylation events and distinguish between direct and indirect effects.

• Phosphorylation sites: While Phospho-STK39 (Ser325) antibody specifically detects Ser325 phosphorylation, WNK kinases primarily phosphorylate STK39 at Thr-231. Consider monitoring multiple phosphorylation sites to gain a comprehensive view of STK39 activation status .

• Downstream effects: Functional activation of STK39 should be reflected in increased phosphorylation of its substrates, including NCC and NKCC2. Parallel assessment of these downstream targets provides confirmation of pathway activation .

• Regulatory context: Environmental factors like osmotic stress, dietary salt, and hormonal stimuli can influence the WNK-STK39 pathway. Document these conditions carefully when interpreting phosphorylation changes .

• Genetic background: Genetic variants in STK39 or WNK kinases may affect baseline phosphorylation levels or responsiveness to stimuli. Consider genotyping or using defined cell lines when comparing across samples .

By integrating these considerations, researchers can more accurately interpret changes in STK39 phosphorylation as indicators of WNK pathway activity and their physiological significance in contexts like blood pressure regulation.

What are key considerations when comparing phospho-STK39 levels across different experimental models?

When comparing phospho-STK39 levels across different experimental models, researchers should consider these key factors to ensure valid comparisons:

How can phospho-proteomic approaches be integrated with antibody-based detection of Phospho-STK39?

Integrating phospho-proteomic approaches with antibody-based detection creates a powerful strategy for comprehensive analysis of STK39 phosphorylation:

• Complementary validation strategy:

  • Use phospho-specific antibodies (like Phospho-STK39 Ser325) to validate mass spectrometry (MS) findings in targeted tissues or conditions.

  • Conversely, use MS to discover and confirm novel STK39 phosphorylation sites beyond those detected by available antibodies.

• Experimental workflow integration:

  • Initial discovery: Apply global phospho-proteomics to identify treatment-responsive phosphorylation sites across the proteome, including STK39.

  • Targeted verification: Follow up with Phospho-STK39 (Ser325) antibody in applications like Western blot, IHC, or ELISA to confirm MS findings in specific cell types or tissues .

  • Functional analysis: Use antibody-based techniques to monitor Ser325 phosphorylation during functional studies of ion transport or blood pressure regulation.

• Quantitative approaches:

  • Parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM) MS methods can provide absolute quantification of STK39 phospho-peptides.

  • Compare MS quantification with antibody-based quantification methods like ELISA or quantitative Western blotting to establish correlation.

• Multi-site phosphorylation analysis:

  • MS can identify multiple phosphorylation sites on STK39 simultaneously, providing a comprehensive phosphorylation profile.

  • Use site-specific antibodies like Phospho-STK39 (Ser325) to investigate the relative timing and regulation of individual sites.

• Pathway context:

  • Phospho-proteomics can reveal changes in the entire WNK-SPAK-cotransporter signaling network.

  • Antibody-based methods can then focus on validating key nodes (like Ser325 phosphorylation) within individual cell types or subcellular compartments .

This integrated approach leverages the global discovery power of phospho-proteomics with the specificity and versatility of antibody-based detection, providing deeper insights into STK39 regulation in physiological and pathological contexts.

What approaches can be used to study the functional consequences of STK39 Ser325 phosphorylation?

To investigate the functional consequences of STK39 Ser325 phosphorylation, researchers can employ several complementary approaches:

• Phospho-mimetic and phospho-null mutations:

  • Generate S325D (mimics phosphorylation) and S325A (prevents phosphorylation) mutants of STK39.

  • Express these in cell lines or animal models to assess effects on:

    • Kinase activity toward substrates like NCC and NKCC2

    • Protein-protein interactions with WNK kinases and cotransporters

    • Subcellular localization

    • Cellular responses to osmotic stress

• Pharmacological modulation:

  • Use specific kinase inhibitors to prevent Ser325 phosphorylation and assess functional consequences.

  • Apply osmotic stress or other stimuli known to activate the WNK-SPAK pathway and monitor Ser325 phosphorylation dynamics with the phospho-specific antibody .

• Physiological measurements:

  • In cell models: Measure ion transport using radioactive isotopes or fluorescent indicators.

  • In animal models: Assess blood pressure, renal sodium handling, and responses to salt loading or diuretics.

  • Correlate these measurements with Ser325 phosphorylation status detected by the antibody .

• Structural biology approaches:

  • Use X-ray crystallography or cryo-EM to determine how Ser325 phosphorylation affects STK39 protein conformation.

  • Apply molecular dynamics simulations to predict effects on protein-protein interaction interfaces.

• Interactome analysis:

  • Perform immunoprecipitation with Phospho-STK39 (Ser325) antibody followed by mass spectrometry to identify phosphorylation-dependent protein interactions .

  • Compare interactome profiles between wild-type STK39 and phospho-mutants.

• Temporal and spatial dynamics:

  • Use the phospho-specific antibody in time-course experiments to determine the kinetics of Ser325 phosphorylation in response to stimuli .

  • Apply immunofluorescence to track subcellular localization changes associated with phosphorylation .

These approaches provide complementary insights into how Ser325 phosphorylation influences STK39 function in molecular, cellular, and physiological contexts, particularly in relation to blood pressure regulation and renal ion transport.

How might Phospho-STK39 (Ser325) antibodies contribute to hypertension research and therapeutic development?

Phospho-STK39 (Ser325) antibodies offer significant potential for advancing hypertension research and therapeutic development through several mechanisms:

• Biomarker development:

  • The antibody enables monitoring of STK39 phosphorylation status as a potential biomarker for WNK pathway activation in hypertensive conditions.

  • This could help stratify hypertension subtypes based on molecular mechanisms, potentially identifying patients who might benefit from targeted therapies .

• Drug discovery platforms:

  • High-throughput screening assays using Phospho-STK39 (Ser325) antibodies can identify compounds that modulate STK39 phosphorylation.

  • Such compounds could form the basis for novel antihypertensive medications targeting the WNK-SPAK-cotransporter pathway, providing alternatives to current diuretics that directly inhibit NCC or NKCC2 .

• Personalized medicine approaches:

  • Genome-wide association studies have linked STK39 variants to blood pressure regulation. Phospho-specific antibodies can help assess how these genetic variants affect STK39 phosphorylation and activation in patient-derived samples.

  • This could enable personalized treatment strategies based on individual patients' STK39 pathway status .

• Mechanistic understanding:

  • The antibody facilitates detailed investigation of how STK39 phosphorylation at Ser325 contributes to blood pressure regulation, potentially revealing new regulatory mechanisms and therapeutic targets.

  • Understanding the temporal and spatial dynamics of STK39 phosphorylation in response to physiological stimuli and pharmacological interventions can refine our models of hypertension pathophysiology .

• Translational research tools:

  • Phospho-STK39 antibodies can be used to assess the efficacy of existing antihypertensive drugs that indirectly affect the WNK-SPAK pathway.

  • They can also help validate new therapeutic approaches in preclinical models before human trials .

As research continues to elucidate the complex role of STK39 in blood pressure regulation, phospho-specific antibodies will remain essential tools for both basic science discoveries and clinical applications in hypertension management.

What emerging technologies might enhance the utility of Phospho-STK39 (Ser325) antibody in research?

Several emerging technologies show promise for enhancing the utility of Phospho-STK39 (Ser325) antibody in research:

• Single-cell phospho-protein analysis:

  • Integration with mass cytometry (CyTOF) or single-cell Western blotting would allow analysis of STK39 phosphorylation heterogeneity across individual cells within tissues.

  • This could reveal subpopulations of cells with distinct STK39 activation states, particularly in the heterogeneous cell types of the nephron .

• Spatial transcriptomics and proteomics:

  • Combining phospho-antibody staining with spatial transcriptomics would correlate STK39 phosphorylation with gene expression patterns in precise anatomical contexts.

  • Technologies like imaging mass cytometry or multiplexed ion beam imaging (MIBI) could map phospho-STK39 in relation to other signaling components with subcellular resolution.

• Biosensor development:

  • FRET-based biosensors incorporating STK39 phospho-recognition domains could enable real-time visualization of STK39 phosphorylation in living cells.

  • Such biosensors would facilitate studies of phosphorylation dynamics in response to osmotic challenges or pharmaceutical interventions.

• Nanobody and aptamer alternatives:

  • Development of phospho-specific nanobodies or aptamers against STK39 Ser325 could provide smaller probes with enhanced tissue penetration for in vivo imaging.

  • These alternatives might overcome some limitations of conventional antibodies in certain applications.

• Microfluidic and organ-on-chip platforms:

  • Integration of phospho-antibodies with kidney-on-chip models would allow analysis of STK39 phosphorylation under physiologically relevant flow conditions.

  • These platforms could facilitate drug screening against STK39 phosphorylation in a more realistic tissue context.

• CRISPR-based phosphorylation reporters:

  • Endogenous tagging of STK39 combined with phospho-specific antibody detection could provide more physiological readouts of phosphorylation events.

  • Such systems avoid artifacts associated with overexpression models.

• AI-assisted image analysis:

  • Machine learning algorithms could enhance the quantitative analysis of phospho-STK39 immunohistochemistry or immunofluorescence data .

  • This would improve detection sensitivity and reproducibility, particularly in complex tissues like kidney.